iBio Dirección

Dirección controles de criterios 2/4

El CEO de iBio es Martin Brenner , nombrado en Jan 2021, tiene una permanencia de 3.83 años. compensación anual total es $1.27M, compuesta por 41.1% salario y 58.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.1% de las acciones de la empresa, por valor de $22.36K. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 7.9 años, respectivamente.

Información clave

Martin Brenner

Chief Executive Officer (CEO)

US$1.3m

Compensación total

Porcentaje del salario del CEO	41.1%
Permanencia del CEO	3.8yrs
Participación del CEO	0.1%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	7.9yrs

Actualizaciones recientes de la dirección

Recent updates

iBio's (NYSEMKT:IBIO) Wonderful 324% Share Price Increase Shows How Capitalism Can Build Wealth

Jan 07

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Martin Brenner en comparación con los beneficios de iBio?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$14m
Jun 30 2024	US$1m	US$522k	-US$15m
Mar 31 2024	n/a	n/a	-US$17m
Dec 31 2023	n/a	n/a	-US$21m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	US$1m	US$458k	-US$29m
Mar 31 2023	n/a	n/a	-US$35m
Dec 31 2022	n/a	n/a	-US$35m
Sep 30 2022	n/a	n/a	-US$32m
Jun 30 2022	US$1m	US$405k	-US$30m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	n/a	n/a	-US$20m
Sep 30 2021	n/a	n/a	-US$21m
Jun 30 2021	US$1m	US$178k	-US$23m

Compensación vs. Mercado: La compensación total de Martin($USD1.27M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD652.28K).

Compensación vs. Ingresos: La compensación de Martin ha aumentado mientras la empresa no es rentable.

CEO

Martin Brenner (54 yo)

3.8yrs

Permanencia

US$1,271,286

Compensación

Dr. Martin B. Brenner DVM., Ph D., is Chief Executive Officer of iBio, Inc. from June 27, 2023 and serves as its Director since June 01, 2024. Dr. Brenner was Interim CEO of iBio, Inc. from January 20, 202...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Martin Brenner	CEO, Chief Scientific Officer & Director	3.8yrs	US$1.27m	0.10% $ 22.4k
Felipe Duran	Chief Financial Officer	1.8yrs	US$761.87k	0.021% $ 4.8k
Marc Banjak	Chief Legal Officer	2.8yrs	sin datos	0.020% $ 4.6k
Kristi Sarno	Senior VP of Business Development	less than a year	sin datos	sin datos

2.3yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de IBIO se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Martin Brenner	CEO, Chief Scientific Officer & Director	less than a year	US$1.27m	0.10% $ 22.4k
Robert Erwin	Member of Scientific Advisory Board	3.9yrs	US$291.75k	sin datos
William Clark	Independent Chairman	3.3yrs	US$89.08k	0% $ 0
Gary Sender	Lead Independent Director	4.1yrs	US$66.00k	0% $ 0
Vidadi Yusibov	Member of Scientific Advisory Board	20.2yrs	sin datos	sin datos
James Hill	Independent Director	16.3yrs	US$55.00k	0.000030% $ 6.7
Timothy Blackwell	Member of Clinical Advisory Board	10.3yrs	sin datos	sin datos
Richard Silver	Member of Clinical Advisory Board	10.3yrs	sin datos	sin datos
J. Huggins	Member of Clinical Advisory Board	10.3yrs	sin datos	sin datos
Thomas Medsger	Member of Clinical Advisory Board	10.2yrs	sin datos	sin datos
Evert Schimmelpennink	Independent Director	5.6yrs	US$56.67k	0% $ 0
Alexandra Kropotova	Independent Director	4.1yrs	US$52.50k	0% $ 0

7.9yrs

Permanencia media

58.5yo

Promedio de edad

Junta con experiencia: La junta directiva de IBIO se considera experimentada (7.9 años de antigüedad promedio).

iBio Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

iBio, Inc., Annual General Meeting, Nov 21, 2024

iBio, Inc. Announces the Appointment of Kristi Sarno as Senior Vice President of Business Development

iBio, Inc., Annual General Meeting, Nov 27, 2023

iBio, Inc. Appoints Dr. Martin Brenner as CEO

iBio, Inc. Appoints Felipe Duran as Interim Chief Financial Officer, Effective as of February 13, 2023

iBio, Inc. Announces Resignation of Robert Lutz, the Chief Financial and Business Officer as an Executive Officer, Effective February 10, 2023

Recent updates

New major risk - Financial position

iBio, Inc., Annual General Meeting, Nov 21, 2024

iBio, Inc. Announces the Appointment of Kristi Sarno as Senior Vice President of Business Development

Texas A&M University System Board of Regents acquired Manufacturing facility located in Bryan, Texas of iBio, Inc. (NYSEAM:IBIO) for $8.5 million.

New major risk - Financial position

iBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC

iBio, Inc. announced that it expects to receive $15.068742 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors

New major risk - Financial position

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $4.780385 million.

New major risk - Financial position

iBio, Inc. Announces Expansion of its AI-Powered Technology Stack with Launch of ShieldTx

iBio, Inc., Annual General Meeting, Nov 27, 2023

New minor risk - Insider selling

New major risk - Market cap size

iBio, Inc. Appoints Dr. Martin Brenner as CEO

iBio, Inc. Announces the Expansion of Its AI-Powered Technology Stack with the Launch of EngageTx

Third quarter 2023 earnings released: US$0.48 loss per share (vs US$1.42 loss in 3Q 2022)

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

First half 2023 earnings released: US$1.93 loss per share (vs US$1.97 loss in 1H 2022)

iBio, Inc. Appoints Felipe Duran as Interim Chief Financial Officer, Effective as of February 13, 2023

iBio, Inc. Announces Resignation of Robert Lutz, the Chief Financial and Business Officer as an Executive Officer, Effective February 10, 2023

High number of new and inexperienced directors

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

iBio, Inc. to Showcase the RubrYc Discovery Engine During Poster Presentations At Antibody Engineering & Therapeutics Conference 2022

iBio, Inc. Announces Executive Changes

iBio, Inc. Announces the Resignation of Thomas F. Isett as a Member of the Board

iBio, Inc. Appoints William D. (Chip) Clark as Chairman

iBio, Inc., Annual General Meeting, Dec 08, 2022

iBio, Inc. Files a Provisional Patent with the United States Patent and Trademark Office Title 'Epidermal Growth Factor Receptor Variant III Antibodies'

iBio, Inc. announced delayed annual 10-K filing

iBio, Inc. to Report Q4, 2022 Results on Sep 27, 2022

iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate

Consensus forecasts updated

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

iBio, Inc. to Report Q3, 2022 Results on May 12, 2022

Price target decreased to US$1.75

Consensus revenue estimates fall by 52%

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

iBio, Inc. to Report Q2, 2022 Results on Feb 14, 2022

iBio, Inc. Shares an Update on Its Lead COVID-19 Vaccine Program, IBIO-202

iBio, Inc Announces Update for its Lead COVID-19 Vaccine Program, IBIO-202, in Light of the Emergence of the Omicron (B.1.1.529) Variant of SARS-CoV-2

Price target decreased to US$2.25

First quarter 2022 earnings released: US$0.041 loss per share (vs US$0.047 loss in 1Q 2021)

iBio, Inc. Provides Revenue Guidance for the First Half, Second Half and Full Year of Fiscal 2022

Full year 2021 earnings released: US$0.12 loss per share (vs US$0.61 loss in FY 2020)

Independent Director Seymour Flug has left the company

High number of new directors

iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate

iBio, Inc.(NYSEAM:IBIO) dropped from Russell Microcap Growth Index

Third quarter 2021 earnings released: US$0.036 loss per share (vs US$0.059 loss in 3Q 2020)

iBio, Inc. Reports Successful Covid-19 Vaccine Toxicology Study Results and Announces Next-Gen Covid-19 Vaccine Program

iBio, Inc. and Fraunhofer USA, Inc. Concludes Litigation

Revenue beats expectations

Second quarter 2021 earnings released: US$0.043 loss per share (vs US$0.69 loss in 2Q 2020)

iBio, Inc. Appoints Robert M. Lutz as Chief Financial & Business Officer, Effective March 4, 2021

iBio, Inc. to Report Q2, 2021 Results on Feb 16, 2021

New 90-day high: US$2.17

iBio's (NYSEMKT:IBIO) Wonderful 324% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: US$1.08

iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer

Price target lowered to US$2.00

iBio, Inc. Announces Resignation of Robert L. Erwin as President

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $32.493644 million.

iBio to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins

iBio, Inc. to Report Q1, 2021 Results on Nov 16, 2020

iBio, Inc. Appoints Randy J. Maddux as Chief Operating Officer, Effective December 1, 2020

iBio, Inc. Announces Appointment of Members to Committees

iBio, Inc. Appoints Gary Sender to Its Board of Directors

iBio, Inc. Announces the Appointment of Linda Armstrong to Board of Directors